Clinical trial
Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
NCT00025350 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00025350 |
|---|---|
| Title | Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer |
| Official title | A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | gefitinib |
| Start date | Oct 1, 2001 |
| Completion | Jun 1, 2006 |
| First posted | Oct 22, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: